Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study.
Coleman BL, Kuster SP, Gubbay J, Scheifele D, Li Y, Low D, Crowcroft N, Mazzulli T, Shi L, Halperin SA, Law B, McGeer A; Working Adults Influenza Cohort Study Group. Coleman BL, et al. Among authors: law b. Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):591-7. doi: 10.1007/s10096-011-1352-5. Epub 2011 Jul 28. Eur J Clin Microbiol Infect Dis. 2012. PMID: 21796343
Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.
Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators. Scheifele DW, et al. Among authors: law b. Pediatr Infect Dis J. 2011 May;30(5):402-7. doi: 10.1097/INF.0b013e3182068f33. Pediatr Infect Dis J. 2011. PMID: 21178654
Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial.
Scheifele DW, Dionne M, Ward BJ, Cooper C, Vanderkooi OG, Li Y, Halperin SA; PHAC/CIHR Influenza Research Network. Scheifele DW, et al. Hum Vaccin Immunother. 2013 Jan;9(1):136-43. doi: 10.4161/hv.22619. Hum Vaccin Immunother. 2013. PMID: 23570051 Free PMC article. Clinical Trial.
Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
Halperin SA, King J, Law B, Mills E, Willems P. Halperin SA, et al. Among authors: law b. Clin Infect Dis. 1999 May;28(5):995-1001. doi: 10.1086/514741. Clin Infect Dis. 1999. PMID: 10452624 Clinical Trial.
Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM, Elrick DB, Jacquet JM. Halperin SA, et al. Among authors: law b. Vaccine. 2006 May 1;24(18):4017-23. doi: 10.1016/j.vaccine.2005.11.012. Epub 2005 Nov 21. Vaccine. 2006. PMID: 16516357 Clinical Trial.
An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA. Langley JM, et al. Among authors: law b. Vaccine. 2007 Jan 22;25(6):1121-5. doi: 10.1016/j.vaccine.2006.09.053. Epub 2006 Oct 2. Vaccine. 2007. PMID: 17045366 Clinical Trial.
976 results